Related Experiment Video
Updated: Aug 31, 2025
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor
Dengyang Zhang1, Chunxiao He1, Yao Guo1
1Edmond H. Fischer Translational Medical Research Laboratory, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China.
Background:
Gastrointestinal stromal tumor (GIST) is a rare type of cancer that occurs in the gastrointestinal tract. The majority of GIST cases carry oncogenic forms of KIT, the receptor for stem cell factor (SCF). Small molecule kinase inhibitor imatinib is effective in prolonging the survival of GIST patients by targeting KIT. However, drug resistance often develops during the therapeutic treatment. Here, we produced a SCF-emtansine drug conjugate (SCF-DM1) with favorable drug efficacy towards GIST cells.
Methods:
Recombinant human SCF (rhSCF) was expressed in E. coli cells and further purified with Ni-NTA Sepharose and Phenyl Sepharose. It was then conjugated with DM1, and the conjugated product SCF-DM1 was evaluated using in vitro cell-based assays and in vivo xenograft mouse model.
Results:
SCF-DM1 was effective in inhibiting imatinib-sensitive and -resistant GIST cell lines and primary tumor cells, with IC50 values of < 30 nM. It induced apoptosis and cell cycle arrest in GIST cells. In xenograft mouse model, SCF-DM1 showed favorable efficacy and safety profiles.
Conclusions:
rhSCF is a convenient and effective vector for drug delivery to KIT positive GIST cells. SCF-DM1 is an effective drug candidate to treat imatinib-sensitive and -resistant GIST.
Insights
A novel drug conjugate, stem cell factor-emtansine (SCF-DM1), effectively targets gastrointestinal stromal tumor (GIST) cells, including imatinib-resistant types. This conjugate shows promise as a new therapeutic strategy for GIST treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Gastrointestinal stromal tumor (GIST) is a rare cancer often driven by KIT mutations.
- Imatinib therapy is effective but limited by acquired drug resistance.
- Targeting KIT, the receptor for stem cell factor (SCF), is a key therapeutic strategy.
Purpose of the Study:
- To develop a novel drug conjugate for GIST treatment.
- To evaluate the efficacy of SCF-emtansine (SCF-DM1) against imatinib-sensitive and -resistant GIST.
- To assess the safety and efficacy of SCF-DM1 in preclinical models.
Main Methods:
- Recombinant human SCF (rhSCF) was produced and purified.
- rhSCF was conjugated with DM1 to create SCF-DM1.
- In vitro cell-based assays and in vivo xenograft mouse models were used for evaluation.
Main Results:
- SCF-DM1 demonstrated potent inhibition of GIST cell lines and primary cells (IC50 < 30 nM).
- The conjugate induced apoptosis and cell cycle arrest in GIST cells.
- SCF-DM1 exhibited favorable efficacy and safety profiles in a xenograft mouse model.
Conclusions:
- Recombinant human SCF serves as an effective drug delivery vector for KIT-positive GIST.
- SCF-DM1 represents a promising drug candidate for treating both imatinib-sensitive and -resistant GIST.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
07:20A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery
Published on: February 28, 2020
